Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Genentech said the US Patent and Trademark Office has rejected the company's claims to its Cabilly patent, a method of producing antibody drugs.
Subscribe to our email newsletter
Genentech stated that, if necessary, it would appeal the decision to reject the patent through all appropriate means of review within the Patent Office and the courts.
The company said the Cabilly patent remains valid and enforceable through the appeals process, which may take approximately one to two years or longer.